Skip to main content

Table 2 Bactericidal efficiency of IgY extracts

From: Production and characterization of anti-Campylobacter jejuni IgY derived from egg yolks

Strain

GR1-CTL

Reduction

GR2-INO

Reduction

GR3-OMP

Reduction

GR4-BACT

Reduction

Homologous

 A2008A

17.35a (6.53)

57.57b (3.39)

50.30b (4.39)

53.20b (17.13)

 B2008A

29.57a (12.60)

95.12bc (5.50)

60.45bd (17.78)

68.20bd (8.05)

 G2008B

21.50a (14.73)

99.61bc (0.44)

48.24bd (26.87)

80.08bd (13.22)

 RM 1221

22.34a (12.52)

49.71c (20.42)

84.11bd (9.79)

64.75b (20.98)

Mean homologous

22.62a (12.41)

79.92bc (24.67)

60.03bd (21.76)

67.35b (17.21)

Heterologous

 81116

34.92 (21.48)

39.07 (22.01)

33.34 (8.97)

33.46 (16.54)

 81-176

34.92 (21.48)

39.07 (22.01)

33.34 (8.97)

33.46 (16.54)

 ATCC 700819

14.42a (5.04)

37.10b (7.76)

42.89b (33.36)

46.31b (3.08)

 ATCC 33291

6.54a (5.17)

26.30b (10.00)

31.53b (12.54)

28.76b (10.96)

Mean heterologous

20.95a (18.58)

34.86b (14.78)

35.55b (9.65)

35.79b (12.88)

  1. Mean reduction percentage of the initial count for the homologous and heterologous strains
  2. () the standard deviation for 3 biological replicates
  3. Homologous C. jejuni strains: A2008A, B2008A, G2008B, RM 1221
  4. Heterologous C. jejuni strains: 81116 and ATCC 33291
  5. On a same row a different than b and c different than d, P < 0.05, Kruskal–Wallis test followed by pairs of Mann–Whitney tests
  6. GR2-INO (orally inoculated), GR3-OMP (immunized with OMP), GR4-BACT (immunized with formalin-killed whole bacteria), GR1-CTL (control group)